A citation-based method for searching scientific literature

P Jaako, A Ugale, M Wahlestedt, T Velasco-Hernandez, J Cammenga, M S Lindström, D Bryder. Leukemia 2017
Times Cited: 2







List of co-cited articles
2 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.
Megan J Bywater, Gretchen Poortinga, Elaine Sanij, Nadine Hein, Abigail Peck, Carleen Cullinane, Meaghan Wall, Leonie Cluse, Denis Drygin, Kenna Anderes,[...]. Cancer Cell 2012
371
100

Identification of RPS14 as a 5q- syndrome gene by RNA interference screen.
Benjamin L Ebert, Jennifer Pretz, Jocelyn Bosco, Cindy Y Chang, Pablo Tamayo, Naomi Galili, Azra Raza, David E Root, Eyal Attar, Steven R Ellis,[...]. Nature 2008
654
100


Mutations of the P53 gene in acute myeloid leukaemia.
P Fenaux, C Preudhomme, I Quiquandon, P Jonveaux, J L Laï, M Vanrumbeke, M H Loucheux-Lefebvre, F Bauters, R Berger, J P Kerckaert. Br J Haematol 1992
119
50

Clinical effect of point mutations in myelodysplastic syndromes.
Rafael Bejar, Kristen Stevenson, Omar Abdel-Wahab, Naomi Galili, Björn Nilsson, Guillermo Garcia-Manero, Hagop Kantarjian, Azra Raza, Ross L Levine, Donna Neuberg,[...]. N Engl J Med 2011
50

Scission of the p53-MDM2 Loop by Ribosomal Proteins.
Xiang Zhou, Jun-Ming Liao, Wen-Juan Liao, Hua Lu. Genes Cancer 2012
52
50

Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype.
Dimitri A Breems, Wim L J Van Putten, Georgine E De Greef, Shama L Van Zelderen-Bhola, Klasien B J Gerssen-Schoorl, Clemens H M Mellink, Aggie Nieuwint, Martine Jotterand, Anne Hagemeijer, H Berna Beverloo,[...]. J Clin Oncol 2008
422
50


MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance.
Brian Kwok, Jeff M Hall, John S Witte, Yin Xu, Prashanti Reddy, Keming Lin, Rachel Flamholz, Bashar Dabbas, Aine Yung, Jenan Al-Hafidh,[...]. Blood 2015
205
50


TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.
Martin Jädersten, Leonie Saft, Alexander Smith, Austin Kulasekararaj, Sabine Pomplun, Gudrun Göhring, Anette Hedlund, Robert Hast, Brigitte Schlegelberger, Anna Porwit,[...]. J Clin Oncol 2011
326
50



Recent Advances in the 5q- Syndrome.
Andrea Pellagatti, Jacqueline Boultwood. Mediterr J Hematol Infect Dis 2015
25
50

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.
Timothy J Ley, Christopher Miller, Li Ding, Benjamin J Raphael, Andrew J Mungall, A Gordon Robertson, Katherine Hoadley, Timothy J Triche, Peter W Laird, Jack D Baty,[...]. N Engl J Med 2013
50


Deletion 5q MDS: molecular and therapeutic implications.
Rami S Komrokji, Eric Padron, Benjamin L Ebert, Alan F List. Best Pract Res Clin Haematol 2013
33
50

Oncogenic Intra-p53 Family Member Interactions in Human Cancers.
Maria Ferraiuolo, Silvia Di Agostino, Giovanni Blandino, Sabrina Strano. Front Oncol 2016
47
50

RNase H of human leukemic cells: a new biological parameter in the study of human leukemias (review).
A D Papaphilis, E F Kamper, S Grammenou, C Kattamis, G A Pangalis. Anticancer Res 1990
4
50

Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53.
L R Livingstone, A White, J Sprouse, E Livanos, T Jacks, T D Tlsty. Cell 1992
50

Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells.
Shilpee Dutt, Anupama Narla, Katherine Lin, Ann Mullally, Nirmalee Abayasekara, Christine Megerdichian, Frederick H Wilson, Treeve Currie, Arati Khanna-Gupta, Nancy Berliner,[...]. Blood 2011
282
50


PP2A: The Achilles Heal in MDS with 5q Deletion.
David A Sallman, Sheng Wei, Alan List. Front Oncol 2014
22
50


Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Español de Citogenética Hematológica.
F Solé, B Espinet, G F Sanz, J Cervera, M J Calasanz, E Luño, F Prieto, I Granada, J M Hernández, J C Cigudosa,[...]. Br J Haematol 2000
197
50

Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells.
Laure A Moutouh-de Parseval, Dominique Verhelle, Emilia Glezer, Kristen Jensen-Pergakes, Gregory D Ferguson, Laura G Corral, Christopher L Morris, George Muller, Helen Brady, Kyle Chan. J Clin Invest 2008
119
50



p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).
Leonie Saft, Mohsen Karimi, Mehran Ghaderi, András Matolcsy, Ghulam J Mufti, Austin Kulasekararaj, Gudrun Göhring, Aristoteles Giagounidis, Dominik Selleslag, Petra Muus,[...]. Haematologica 2014
90
50

Wnt/beta-catenin signaling: components, mechanisms, and diseases.
Bryan T MacDonald, Keiko Tamai, Xi He. Dev Cell 2009
50


Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.
Alan List, Gordon Dewald, John Bennett, Aristotle Giagounidis, Azra Raza, Eric Feldman, Bayard Powell, Peter Greenberg, Deborah Thomas, Richard Stone,[...]. N Engl J Med 2006
940
50

An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control.
A Gualberto, K Aldape, K Kozakiewicz, T D Tlsty. Proc Natl Acad Sci U S A 1998
210
50

Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.
Aristoteles Giagounidis, Ghulam J Mufti, Pierre Fenaux, Ulrich Germing, Alan List, Kyle J MacBeth. Ann Hematol 2014
29
50

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.
Pierre Fenaux, Aristoteles Giagounidis, Dominik Selleslag, Odile Beyne-Rauzy, Ghulam Mufti, Moshe Mittelman, Petra Muus, Peter Te Boekhorst, Guillermo Sanz, Consuelo Del Cañizo,[...]. Blood 2011
324
50

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.
R Itzykson, O Kosmider, T Cluzeau, V Mansat-De Mas, F Dreyfus, O Beyne-Rauzy, B Quesnel, N Vey, V Gelsi-Boyer, S Raynaud,[...]. Leukemia 2011
360
50

Cooperating gene mutations in acute myeloid leukemia: a review of the literature.
A Renneville, C Roumier, V Biggio, O Nibourel, N Boissel, P Fenaux, C Preudhomme. Leukemia 2008
248
50

Gene expression profiling of CD34+ cells in patients with the 5q- syndrome.
Jacqueline Boultwood, Andrea Pellagatti, Helen Cattan, Charles H Lawrie, Aristoteles Giagounidis, Luca Malcovati, Matteo G Della Porta, Martin Jädersten, Sally Killick, Carrie Fidler,[...]. Br J Haematol 2007
120
50

Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.
Shengliang Zhang, Lanlan Zhou, Bo Hong, A Pieter J van den Heuvel, Varun V Prabhu, Noel A Warfel, Christina Leah B Kline, David T Dicker, Levy Kopelovich, Wafik S El-Deiry. Cancer Res 2015
68
50

Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41.
Ashley A Basiorka, Kathy L McGraw, Leentje De Ceuninck, Lori N Griner, Ling Zhang, Justine A Clark, Gisela Caceres, Lubomir Sokol, Rami S Komrokji, Gary W Reuther,[...]. Cancer Res 2016
21
50

A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes.
Jing Fang, Xiaona Liu, Lyndsey Bolanos, Brenden Barker, Carmela Rigolino, Agostino Cortelezzi, Esther N Oliva, Maria Cuzzola, H Leighton Grimes, Celia Fontanillo,[...]. Nat Med 2016
52
50

Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
Jan M Middeke, Min Fang, Jan J Cornelissen, Brigitte Mohr, Frederick R Appelbaum, Michael Stadler, Jaime Sanz, Herrad Baurmann, Gesine Bug, Kerstin Schäfer-Eckart,[...]. Blood 2014
43
50

International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome.
Y Kita-Sasai, S Horiike, S Misawa, H Kaneko, M Kobayashi, M Nakao, H Nakagawa, H Fujii, M Taniwaki. Br J Haematol 2001
66
50


Inhibition of HDM2 and activation of p53 by ribosomal protein L23.
Aiwen Jin, Koji Itahana, Kevin O'Keefe, Yanping Zhang. Mol Cell Biol 2004
288
50

Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
Raynier Devillier, Véronique Mansat-De Mas, Veronique Gelsi-Boyer, Cecile Demur, Anne Murati, Jill Corre, Thomas Prebet, Sarah Bertoli, Mandy Brecqueville, Christine Arnoulet,[...]. Oncotarget 2015
48
50

Identification of a functional link for the p53 tumor suppressor protein in dexamethasone-induced growth suppression.
Gudrun Urban, Teresa Golden, Ileana V Aragon, Lex Cowsert, Scott R Cooper, Nicholas M Dean, Richard E Honkanen. J Biol Chem 2003
43
50



Deletions linked to TP53 loss drive cancer through p53-independent mechanisms.
Yu Liu, Chong Chen, Zhengmin Xu, Claudio Scuoppo, Cory D Rillahan, Jianjiong Gao, Barbara Spitzer, Benedikt Bosbach, Edward R Kastenhuber, Timour Baslan,[...]. Nature 2016
136
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.